4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Care in Diabetes—2023
NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2022 - pmc.ncbi.nlm.nih.gov
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …
ADA's current clinical practice recommendations and is intended to provide the components …
Steatotic liver disease: pathophysiology and emerging pharmacotherapies
Steatotic liver disease (SLD) displays a dynamic and complex disease phenotype.
Consequently, the metabolic dysfunction-associated steatotic liver disease …
Consequently, the metabolic dysfunction-associated steatotic liver disease …
A phase 2 randomized trial of survodutide in MASH and fibrosis
AJ Sanyal, P Bedossa, M Fraessdorf… - … England Journal of …, 2024 - Mass Medical Soc
Background Dual agonism of glucagon receptor and glucagon-like peptide-1 (GLP-1)
receptor may be more effective than GLP-1 receptor agonism alone for treating metabolic …
receptor may be more effective than GLP-1 receptor agonism alone for treating metabolic …
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
European Association for the Study of the Liver (EASL)… - Obesity Facts, 2024 - karger.com
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-
alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the …
alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the …
Global burden of metabolic diseases, 1990–2021
Background Common metabolic diseases, such as type 2 diabetes mellitus (T2DM),
hypertension, obesity, hypercholesterolemia, and metabolic dysfunction-associated steatotic …
hypertension, obesity, hypercholesterolemia, and metabolic dysfunction-associated steatotic …
Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis …
Objective Metabolic dysfunction-associated steatotic liver disease (MASLD) and
cardiometabolic conditions affect populations across economic strata. Nevertheless, there …
cardiometabolic conditions affect populations across economic strata. Nevertheless, there …
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions
Globally, nearly half of deaths from cirrhosis and chronic liver diseases (CLD) and three-
quarters of deaths from hepatocellular carcinoma (HCC) occur in the Asia-Pacific region …
quarters of deaths from hepatocellular carcinoma (HCC) occur in the Asia-Pacific region …
Expert panel recommendations: practical clinical applications for initiating and monitoring resmetirom in patients with MASH/NASH and moderate to noncirrhotic …
M Noureddin, MR Charlton, SA Harrison… - Clinical …, 2024 - Elsevier
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects one in four people
in the United States and western Europe, with an important proportion develo** metabolic …
in the United States and western Europe, with an important proportion develo** metabolic …
Steatotic liver disease
Steatotic liver disease is the overarching term for conditions characterised by abnormal lipid
accumulation in the liver (liver or hepatic steatosis). Steatotic liver disease encompasses …
accumulation in the liver (liver or hepatic steatosis). Steatotic liver disease encompasses …
Glucagon promotes increased hepatic mitochondrial oxidation and pyruvate carboxylase flux in humans with fatty liver disease
We assessed in vivo rates of hepatic mitochondrial oxidation, gluconeogenesis, and β-
hydroxybutyrate (β-OHB) turnover by positional isotopomer NMR tracer analysis (PINTA) in …
hydroxybutyrate (β-OHB) turnover by positional isotopomer NMR tracer analysis (PINTA) in …